U.S. pharma large copyright scrapped two experimental weight loss products final year—a after-every day capsule, lotiglipron, because of elevated liver enzymes plus a 2 times-each day capsule, danuglipron, resulting from robust Uncomfortable side effects—but CEO Albert Bourla has stated the company is determined to “Engage in and acquire” f